The federal government has now named the drugs that will move from upfront discounts to after-the-fact rebates in the 340B program on Jan. 1. The Health Resources and Services Administration approved plans from 10 drugmakers covering 21 medicines, including widely used drugs such as Eliquis, Jardiance, Farxiga and Januvia.
The list, posted Oct. 1 on HRSA's pilot program page, includes AbbVie, Amgen, Astellas, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, GSK, Merck, Pfizer and Teva. It is larger than the government's first attempt at the pilot, which a federal court blocked before it could start.
